NCT01844986 · BASELINE

Baseline characteristics

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. · Source last updated 2025-12-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

counts
group Id
BG000
value
300
group Id
BG001
value
150
group Id
BG002
value
450
units
Participants

groups

description
Taken orally twice daily
id
BG000
title
Olaparib 300mg Tablets (Global Cohort & China Cohort)
description
Taken orally twice daily
id
BG001
title
Placebo Tablets (Global Cohort & China Cohort)
description
Total of all reporting groups
id
BG002
title
Total

measures

classes
categories
measurements
group Id
BG000
spread
9.38
value
53.6
group Id
BG001
spread
9.79
value
53.4
group Id
BG002
spread
9.51
value
53.5
denoms
counts
group Id
BG000
value
260
group Id
BG001
value
131
group Id
BG002
value
391
units
Participants
title
Global Cohort
categories
measurements
group Id
BG000
spread
7.27
value
50.7
group Id
BG001
spread
7.95
value
51.5
group Id
BG002
spread
7.44
value
51.0
denoms
counts
group Id
BG000
value
44
group Id
BG001
value
20
group Id
BG002
value
64
units
Participants
title
China Cohort
dispersion Type
STANDARD_DEVIATION
param Type
MEAN
population Description
Each study is reported in a separate row. There were 4 participants who were in both the Global and China Olaparib Arm, and 1 participant in both the Global and China Placebo Arm.
title
Age, Continuous
unit Of Measure
Years
classes
categories
measurements
group Id
BG000
value
260
group Id
BG001
value
131
group Id
BG002
value
391
title
Female
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
Male
denoms
counts
group Id
BG000
value
260
group Id
BG001
value
131
group Id
BG002
value
391
units
Participants
title
Global Cohort
categories
measurements
group Id
BG000
value
44
group Id
BG001
value
20
group Id
BG002
value
64
title
Female
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
Male
denoms
counts
group Id
BG000
value
44
group Id
BG001
value
20
group Id
BG002
value
64
units
Participants
title
China Cohort
param Type
COUNT_OF_PARTICIPANTS
population Description
Each study is reported in a separate row. There were 4 participants who were in both the Global and China Olaparib Arm, and 1 participant in both the Global and China Placebo Arm.
title
Sex: Female, Male
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
1
group Id
BG002
value
1
title
American Indian or Alaska Native
measurements
group Id
BG000
value
39
group Id
BG001
value
20
group Id
BG002
value
59
title
Asian
measurements
group Id
BG000
value
1
group Id
BG001
value
1
group Id
BG002
value
2
title
Native Hawaiian or Other Pacific Islander
measurements
group Id
BG000
value
2
group Id
BG001
value
2
group Id
BG002
value
4
title
Black or African American
measurements
group Id
BG000
value
214
group Id
BG001
value
106
group Id
BG002
value
320
title
White
measurements
group Id
BG000
value
1
group Id
BG001
value
0
group Id
BG002
value
1
title
More than one race
measurements
group Id
BG000
value
3
group Id
BG001
value
1
group Id
BG002
value
4
title
Unknown or Not Reported
denoms
counts
group Id
BG000
value
260
group Id
BG001
value
131
group Id
BG002
value
391
units
Participants
title
Global Cohort
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
American Indian or Alaska Native
measurements
group Id
BG000
value
44
group Id
BG001
value
20
group Id
BG002
value
64
title
Asian
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
Native Hawaiian or Other Pacific Islander
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
Black or African American
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
White
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
More than one race
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
Unknown or Not Reported
denoms
counts
group Id
BG000
value
44
group Id
BG001
value
20
group Id
BG002
value
64
units
Participants
title
China Cohort
param Type
COUNT_OF_PARTICIPANTS
population Description
Each study is reported in a separate row. There were 4 participants who were in both the Global and China Olaparib Arm, and 1 participant in both the Global and China Placebo Arm.
title
Race (NIH/OMB)
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
213
group Id
BG001
value
107
group Id
BG002
value
320
title
Complete Response
measurements
group Id
BG000
value
47
group Id
BG001
value
24
group Id
BG002
value
71
title
Partial Response
denoms
counts
group Id
BG000
value
260
group Id
BG001
value
131
group Id
BG002
value
391
units
Participants
title
Global Cohort
categories
measurements
group Id
BG000
value
37
group Id
BG001
value
18
group Id
BG002
value
55
title
Complete Response
measurements
group Id
BG000
value
7
group Id
BG001
value
2
group Id
BG002
value
9
title
Partial Response
denoms
counts
group Id
BG000
value
44
group Id
BG001
value
20
group Id
BG002
value
64
units
Participants
title
China Cohort
param Type
COUNT_OF_PARTICIPANTS
population Description
Each study is reported in a separate row. There were 4 participants who were in both the Global and China Olaparib Arm, and 1 participant in both the Global and China Placebo Arm.
title
Response to previous platinum chemotherapy (as randomised)
unit Of Measure
Participants

population Description

Global Cohort (391 subjects): 260 Olaparib 131 Placebo China Cohort (64 subjects): 44 Olaparib 20 Placebo Included in both cohorts (5 subjects): 4 Olaparib 1 Placebo Total (450 subjects): 300 Olaparib 150 Placebo

Complete source fields

denoms

counts
group Id
BG000
value
300
group Id
BG001
value
150
group Id
BG002
value
450
units
Participants

groups

description
Taken orally twice daily
id
BG000
title
Olaparib 300mg Tablets (Global Cohort & China Cohort)
description
Taken orally twice daily
id
BG001
title
Placebo Tablets (Global Cohort & China Cohort)
description
Total of all reporting groups
id
BG002
title
Total

measures

classes
categories
measurements
group Id
BG000
spread
9.38
value
53.6
group Id
BG001
spread
9.79
value
53.4
group Id
BG002
spread
9.51
value
53.5
denoms
counts
group Id
BG000
value
260
group Id
BG001
value
131
group Id
BG002
value
391
units
Participants
title
Global Cohort
categories
measurements
group Id
BG000
spread
7.27
value
50.7
group Id
BG001
spread
7.95
value
51.5
group Id
BG002
spread
7.44
value
51.0
denoms
counts
group Id
BG000
value
44
group Id
BG001
value
20
group Id
BG002
value
64
units
Participants
title
China Cohort
dispersion Type
STANDARD_DEVIATION
param Type
MEAN
population Description
Each study is reported in a separate row. There were 4 participants who were in both the Global and China Olaparib Arm, and 1 participant in both the Global and China Placebo Arm.
title
Age, Continuous
unit Of Measure
Years
classes
categories
measurements
group Id
BG000
value
260
group Id
BG001
value
131
group Id
BG002
value
391
title
Female
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
Male
denoms
counts
group Id
BG000
value
260
group Id
BG001
value
131
group Id
BG002
value
391
units
Participants
title
Global Cohort
categories
measurements
group Id
BG000
value
44
group Id
BG001
value
20
group Id
BG002
value
64
title
Female
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
Male
denoms
counts
group Id
BG000
value
44
group Id
BG001
value
20
group Id
BG002
value
64
units
Participants
title
China Cohort
param Type
COUNT_OF_PARTICIPANTS
population Description
Each study is reported in a separate row. There were 4 participants who were in both the Global and China Olaparib Arm, and 1 participant in both the Global and China Placebo Arm.
title
Sex: Female, Male
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
1
group Id
BG002
value
1
title
American Indian or Alaska Native
measurements
group Id
BG000
value
39
group Id
BG001
value
20
group Id
BG002
value
59
title
Asian
measurements
group Id
BG000
value
1
group Id
BG001
value
1
group Id
BG002
value
2
title
Native Hawaiian or Other Pacific Islander
measurements
group Id
BG000
value
2
group Id
BG001
value
2
group Id
BG002
value
4
title
Black or African American
measurements
group Id
BG000
value
214
group Id
BG001
value
106
group Id
BG002
value
320
title
White
measurements
group Id
BG000
value
1
group Id
BG001
value
0
group Id
BG002
value
1
title
More than one race
measurements
group Id
BG000
value
3
group Id
BG001
value
1
group Id
BG002
value
4
title
Unknown or Not Reported
denoms
counts
group Id
BG000
value
260
group Id
BG001
value
131
group Id
BG002
value
391
units
Participants
title
Global Cohort
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
American Indian or Alaska Native
measurements
group Id
BG000
value
44
group Id
BG001
value
20
group Id
BG002
value
64
title
Asian
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
Native Hawaiian or Other Pacific Islander
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
Black or African American
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
White
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
More than one race
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
title
Unknown or Not Reported
denoms
counts
group Id
BG000
value
44
group Id
BG001
value
20
group Id
BG002
value
64
units
Participants
title
China Cohort
param Type
COUNT_OF_PARTICIPANTS
population Description
Each study is reported in a separate row. There were 4 participants who were in both the Global and China Olaparib Arm, and 1 participant in both the Global and China Placebo Arm.
title
Race (NIH/OMB)
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
value
213
group Id
BG001
value
107
group Id
BG002
value
320
title
Complete Response
measurements
group Id
BG000
value
47
group Id
BG001
value
24
group Id
BG002
value
71
title
Partial Response
denoms
counts
group Id
BG000
value
260
group Id
BG001
value
131
group Id
BG002
value
391
units
Participants
title
Global Cohort
categories
measurements
group Id
BG000
value
37
group Id
BG001
value
18
group Id
BG002
value
55
title
Complete Response
measurements
group Id
BG000
value
7
group Id
BG001
value
2
group Id
BG002
value
9
title
Partial Response
denoms
counts
group Id
BG000
value
44
group Id
BG001
value
20
group Id
BG002
value
64
units
Participants
title
China Cohort
param Type
COUNT_OF_PARTICIPANTS
population Description
Each study is reported in a separate row. There were 4 participants who were in both the Global and China Olaparib Arm, and 1 participant in both the Global and China Placebo Arm.
title
Response to previous platinum chemotherapy (as randomised)
unit Of Measure
Participants

population Description

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice